Sarepta Therapeutics
SRPT | NASDAQ
$15.13
-$0.94 (-5.85%)
At close: Nov 16, 2026, 4:00 PM ET
$15.20
+$0.07 (+0.46%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Sarepta Therapeutics Company Profile
Company profile explainedCompany Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Michael E. Severino | Chief Executive Officer & Director |
| Alison Nasisi | Executive Vice President & Chief People Officer |
| Ian Michael Estepan | President & Chief Operating Officer |
| Ryan H. Wong | Executive Vice President & Chief Financial Officer |
| Cristin L. Rothfuss | Executive Vice President, General Counsel & Company Secretary |
| Diane L. Berry | Executive Vice President and Chief of Global Policy & Advocacy Officer |
| Douglas S. Ingram | Advisor |
| Louise R. Rodino-Klapac | President of Research & Development and Technical Operations |
| Rachael Potter | Chief Scientific Officer |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Aug 14, 2026 | 13F-HR | Quarterly report filed by institutional managers, ... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | 8-K | Current Report |
| Aug 05, 2026 | 10-Q | Quarterly Report |
Sarepta Therapeutics
| Country | United States |
| IPO Date | Jun 4, 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 835 |
| CEO | Michael E. Severino |
Contact Details
215 First Street Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | SRPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000873303 |
| CUSIP Number | 803607100 |
| ISIN Number | US8036071004 |
| SIC Code | 2834 |
Recent News
- 7 days ago / marketbeat.comSarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
- 9 days ago / seekingalpha.comSarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript
- 11 days ago / zacks.comSRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
- 11 days ago / marketbeat.comSarepta Therapeutics Q3 Earnings Call Highlights
- 11 days ago / zacks.comCompared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
- 19 days ago / zacks.comSarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
- 21 days ago / businesswire.comSarepta Therapeutics to Present at Upcoming Investor Conferences
- 26 days ago / businesswire.comSarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- 1 month ago / businesswire.comSarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
- 1 month ago / benzinga.comJim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'
Add to Watchlist
Select watchlists to add or remove SRPT